Abstract:BACKGROUND:Glioblastoma (GBM) is the most common and lethal intracranial malignancy in adults, with dismal prognosis despite multimodal therapies. Tectonic family member 1 (TCTN1) is a protein involved in a diverse range of developmental processes, yet its functions in GBM remain unclear. This study aims to investigate expression profile, prognostic value and effects of TCTN1 gene in GBM.METHODS:Protein levels of TCTN1 were assessed by immunohistochemical staining using a tissue microarray constructed by a Chinese cohort of GBM patients (n=110), and its mRNA expression was also detected in a subset of this cohort. Kaplan-Meier analysis and Cox regression were performed to estimate the prognostic significance of TCTN1. Similar analyses were also conducted in another two independent cohorts: The Cancer Genome Atlas (TCGA) cohort (n=528) and the Repository for Molecular Brain Neoplasia Data (REMBRANDT) cohort (n=228). For the TCGA cohort, the relationships between TCTN1 expression, clinical outcome, molecular subtypes and genetic alterations were also analysed. Furthermore, proliferation of TCTN1 overexpressed or silenced GBM cells was determined by CCK-8 assays.RESULTS:As discovered in three independent cohorts, both mRNA and protein levels of TCTN1 expression were markedly elevated in human GBMs, and higher TCTN1 expression served as an independent prognostic factor predicting poorer prognosis of GBM patients. Additionally, in the TCGA cohort, TCTN1 expression was dramatically decreased in patients within the proneural subtype compared to other subtypes, and significantly influenced by the status of several genetic aberrations such as CDKN2A/B deletion, EGFR amplification, PTEN deletion and TP53 mutation. The prognostic value of TCTN1 was more pronounced in proneural and mesenchymal subtypes, and was also affected by several genetic alterations particularly PTEN deletion. Furthermore, overexpression of TCTN1 significantly promoted proliferation of GBM cells, while its depletion evidently hampered cell growth.CONCLUSIONS:TCTN1 is elevated in human GBMs and predicts poor clinical outcome for GBM patients, which is associated with molecular subtypes and genetic features of GBMs. Additionally, TCTN1 expression impacts GBM cell proliferation. Our results suggest for the first time that TCTN1 may serve as a novel prognostic factor and a potential therapeutic target for GBM.

CAMTA1, a novel antitumor gene, regulates proliferation and the cell cycle in glioma by inhibiting AKT phosphorylation

Characterization of CAMTA1, a Putative 1p36 Cancer Gene: Effects on Cell Cycle and Gene Expression

CAMK1D Inhibits Glioma Through the PI3K/AKT/mTOR Signaling Pathway

TUBA1C expression promotes proliferation by regulating the cell cycle and indicates poor prognosis in glioma

Overexpression of CAMK 2 N 1 indicates good prognosis for glioma and regulates androgen receptor-associated cell proliferation and apoptosis

AKT2-knockdown Suppressed Viability with Enhanced Apoptosis, and Attenuated Chemoresistance to Temozolomide of Human Glioblastoma Cells in Vitro and in Vivo.

TMBIM1 Promotes EMT by Stimulating Autophagic Degradation of E-cadherin Via AMPK/mTOR/ULK1 Axis in Human Gliomas

CMTM Family Genes Affect Prognosis and Modulate Immunocytes Infiltration in Grade II/III Glioma Patients by Influencing the Tumor Immune Landscape and Activating Associated Immunosuppressing Pathways

Expression and Prognostic Significance of TCTN1 in Human Glioblastoma

Chromatin Licensing and DNA Replication Factor 1 (CDT1) Is a Potential Prognostic Biomarker Involved in the Malignant Biological Behavior of Glioma

Casein kinase 1 (CK1) promotes the proliferation and metastasis of glioma cells via the phosphatidylinositol 3 kinase-matrix metalloproteinase 2 (AKT-MMP2) pathway

CMTM6 Knockdown Prevents Glioma Progression by Inactivating the Mtor Pathway

Identification Key Genes Influence Cell Cycle Process in Glioma by Bioinformatics Analysis

Up-regulation of LPCAT1 is correlated with poor prognosis and promotes tumor progression in glioblastoma

Cysteine cathepsin C: a novel potential biomarker for the diagnosis and prognosis of glioma

Prognostic Role of METTL1 in Glioma

Integrated bioinformatics analysis and experimental validation identified CDCA families as prognostic biomarkers and sensitive indicators for rapamycin treatment of glioma

Downregulation of TET1 Promotes Glioma Cell Proliferation and Invasion by Targeting Wnt/ β-Catenin Pathway

TMEM60 Promotes the Proliferation and Migration and Inhibits the Apoptosis of Glioma Through Modulating AKT Signaling

High β-catenin/Tcf-4 activity confers glioma progression via direct regulation of AKT2 gene expression.

TMBIM1 Promotes Proliferation and Attenuates Apoptosis in Glioblastoma Cells by Targeting the P38 MAPK Signalling Pathway.